Why Analysts Believe RAC is “Highly Undervalued”, page-4

IMO. DYOR.

I think a key to closing some of this share price gap will likely be a partnership with an upfront cash payment plus various clinical development and commercial milestones.

Partnerships can come with US $50M plus upfront cash payments. An upfront + milestones partnership would fund pivotal trials and potentially be a stepping stone to a buyout transaction.

RACE shared the following deal examples in 2021 ( and these were preclinical stage ) - these also in the emerging RNA regulation space RACE is partly focused on.



Zantrene is also not a “me too” drug. RACE with FTO and cardioprotection ( with improved cancer killing ) seems to be firmly establishing a lead position in key Oncology Real Estate … targeting FTO for a large number of cancers and a better ( and importantly safer ) chemo regimen to replace the mainstream AC regimen. RACE have been undertaking their own preclinical programs to show improved efficacy / safety and have various programs to validate this through proof of concept clinical trials.



Note - above slide is from a July 2022 Torreya presentation available here:

https://torreya.com/publications/Torreya-Oncology-Marketplace-Update-July_19_2022.pdf